HTB

COVID-19: investigational drugs

CROI 2021: New compounds for prevention and treatment of COVID-19

Oral molnupiravir at higher dose reduces SARS-CoV-2 viral load at day five in small phase 2 study

Bamlanivimab prophylaxis reduces hospitalisation and mortality: results from phase 3 BLAZE-2 study

Dual Eli-Lilly mAb bamlanivimab and etesevimab reduces hospitalisation after single infusion: results from BLAZE-1 study

Dual Regeneron mAbs casirivimab with imdevimab reduce transmission: interim results from phase 3 study

CROI 2021: Urgency of global access to vaccines, the potential of mAbs and the lessons learned from HIV

Baricitinib improves recovery in sub-group of adults hospitalised COVID-19: results from ACTT-2 study

Ivermectin has no impact in treating mild COVID-19 in 400 adults in Columbia

No benefit from BRII and GSK monoclonal antibodies against COVID-19 in ACTIV-3 study

Tocilizimab effectively reduces COVID-19 related deaths and hospitalisation time: additive benefit with dexamethasone

Bamlanivimab (LY-CoV555) prophylaxis prevents COVID-19 in care homes: results of BLAZE-2 study

US FDA specifies high antibody titre for convalescent plasma and to only use in early COVID-19

No benefit from convalescent plasma in UK RECOVERY study: limited results restrict implications for COVID-19

Merck/MSD withdraws two vaccine candidates from further research but continues focus on treatment

Oral colchicine reduces hospitalisation in international randomised phase 3 outpatient study

IL-6 agonists tocilizumab and sarilumab reduces mortality in severe COVID-19: interim results from REMAP-CAP study

Two different dual antibody treatments each reduce SARS-CoV-2 viral load by >0.5 log

IV methylprednisolone pulse treatment for hospitalised severe COVID-19

Monoclonal antibody bamlanivimab is not effective in advanced COVID-19: lack of early signal stops study early

Azithromycin monotherapy shows no benefit for COVID-19: RECOVERY study reports 1493 further deaths

Hydroxychloroquine fails to prevent COVID-19 or SARS-CoV-2 transmission when used as PEP

Hydroxychloroquine has no benefit on symptoms at 14 days

WHO SOLIDARITY study published in NEJM

International COVID-19 study launches in Africa but with drugs that have little chance of working (ANTICOV)

Remdesivir given full approval by the US FDA, but on limited data

DSMB stops REGN-COV2 (casirivimab/imdevimab) monoclonal antibody study in people with high-flow oxygen or ventilation: implications for UK RECOVERY study

Monoclonal antibody stopped in ACTIV-3 study: bamlanivimab shows lack of benefit in people hospitalised with COVID-19

Convalescent plasma: randomised controlled study finds no benefit in moderate stage COVID-19

No survival benefit from remdesivir, hydroxychloroquine, lopinavir/r or interferon-β1a in moderate and severe COVID-19: interim results from the WHO SOLIDARITY study

COVID-19: pathogenesis and treatment 

Tocilizumab fails to meet clinical endpoints in randomised COVACTA study: other studies continue

Tocilizumab associated with better outcomes from COVID-19 in US study

Famotidine associated with better outcomes from COVID-19

INSIGHT network to study monoclonal antibodies for COVID-19 including LY-CoV555

HepC drugs for COVID-19: sofosbuvir/daclatasvir show faster recovery and reduced mortality

Predictors of response to remdesivir in GS-5773 COVID-19 study

UK study reports inhaled interferon-Beta reduces time to recovery from COVID-19

EMA grants conditional approval for remdesivir in the EU to treat COVID-19

RECOVERY study reports that lopinavir/r fails to show benefit against COVID-19

Hydroxychloroquine and lopinavir/r arms stopped in the WHO SOLIDARITY study

Individualising management of COVID-19 based on real-time inflammatory responses

Further positive reports from tocilizumab to treat COVID-19

Dexamethasone significantly reduces mortality in subset of patients hospitalised with advanced COVID-19: UK RECOVERY study

Modelling paper suggests hydroxychloroquine dosing was too low to be active against COVID-19 and that higher doses would risk toxicity

FDA contraindication for remdesivir and hydroxychloroquine (HCQ): immediate impact on current HCQ research

UK RECOVERY study stops hydroxychloroquine (HCQ) for COVID-19: more than 1100 deaths question ethics and safety overall

SIMPLE study reports benefit from 5-day but not 10-day remdesivir on moderate COVID-19

Recent papers on convalescent plasma and on ACE inhibitors and angiotensin receptor blockers

Remdesivir improves recovery time in early COVID-19 infection: first definitive results of benefit

Convalescent plasma therapy for COVID-19

Treatment with interferon in early COVID-19

Famotidine associated with improved clinical outcomes in people hospitalised with COVID-19

Tocilizumab and remdesivir in new dual therapy study

RETRACTED – Re: No benefit from hydroxychloroquine, with or without macrolide antibiotics in analysis of 96,000 patients

Remdesivir for COVID-19: randomised study shows similar antiviral effect to placebo

Other remdesivir news: top results from NIH and Gilead studies – emergency approval in US and Japan

Potential for tocilizumab to treat moderate to severe COVID-19

Detectable viral load and IL-6: a role for tocilizumab or anti-JAK inhibitor baricitinib?

Rheumatoid arthritis drug anakinra in small study to treat COVID-19

Anticoagulants associated with improved survival rates in people hospitalised with COVID-19

Monoclonal antibodies identified in convalescent plasma COVID-19

Studies reporting lack of benefit from hydroxychloroquine to treat COVID-19

Israeli cohort shows no protection against COVID-19 from childhood BCG vaccination

Remdesivir for COVID-19: first results from compassionate access programme

No benefit of hydroxychloroquine and azithromycin in people hospitalised with COVID-19

Post navigation